Imiquimod

Imiquimod

CAT N°: 14956
Price:

216.00 183.60

216.00 183.60

Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 ?M).{23982} It increases TNF-? and IL-12 p40 production in IFN-?-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.{23979} Topical application of imiquimod (30 ?l of 5% cream) increases TNF and IFN levels at the application site in hairless mice.{43540} Imiquimod dose-dependently increases serum levels of IFN-? in mice when administered by gavage.{43541} It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.{43542} Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
  • Correlated keywords
    • 99011-78-6 receptors agonists antiviral anti viral anti-viral inflammation signals transduction immune responses infectious diseases cancers OGFs opioid growth factors imidazoquinoline toll-like tolls like 7 TLR7 TLR-7 TLRs IFN-? IFN-alpha IFN-.alpha. IFN-a INF? INFa INFalpha INF.alpha. INFs ? a alpha .alpha. IL-12 ILs 12 IL12 12 interleukins interferons anti-tumors antitumors tumors topically topical R837 Rs 837 TMX101 TMXs TMX-101 101 S 26308 S26308 Aldara Beselna Zyclara
  • Product Overview:
    Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 ?M).{23982} It increases TNF-? and IL-12 p40 production in IFN-?-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.{23979} Topical application of imiquimod (30 ?l of 5% cream) increases TNF and IFN levels at the application site in hairless mice.{43540} Imiquimod dose-dependently increases serum levels of IFN-? in mice when administered by gavage.{43541} It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.{43542} Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.

We also advise you